After Receiving a Custom Experimental Medicine, a Teen With a Rare Genetic Disorder Walked on His Own for the First Time

A seventeen-year-old named Connor Dalby recently achieved a significant milestone by walking unassisted for the first time in his life. Connor lives with a rare genetic mutation that previously triggered up to 100 seizures a day. Standard anti-seizure medications provided no relief, and his medical prognosis remained dire during his early childhood.

The breakthrough arrived in the form of a custom experimental medicine. After three years of development, researchers created a tailor-made drug specifically for Connor's unique genetic profile. The treatment involves spinal injections administered every few months. Since beginning the therapy, Connor has seen his seizure frequency drop by 90 percent. He also experienced a major increase in his seizure-free days, moving from zero to nearly half of his days without a medical event.

This study, published in Nature Medicine, highlights the potential of what is known as n-of-one medicine. When a genetic mutation is too rare for a large-scale clinical trial, scientists can design treatments for individual patients. Connor’s treatment was funded and created by the n-Lorem Foundation, a nonprofit established by Stanley Crooke. The foundation focuses on developing medicines for patients with mutations too rare to attract commercial pharmaceutical interest.

While the results in Connor’s case are substantial, medical experts note that these therapies come with limitations. The drugs do not alter the patient’s DNA, meaning repeated spinal injections are necessary to maintain the progress. Furthermore, the results of n-of-one treatments vary by individual, as seen in the second participant in the study who showed a different level of improvement. Despite these challenges, researchers are encouraged by the evidence that neurological issues previously considered permanent can see improvement through targeted intervention.

The development of these personalized therapies raises questions about how to manage such treatments within larger health systems. Scaling production and ensuring access remain hurdles for the medical community. However, for families like Connor’s, the ability to address specific genetic errors offers a new path for those previously left without options.